AbbVie Reports First-Quarter 2025 Financial Results
-- Reports First-Quarter Diluted EPS of $0.72 on a GAAP Basis, a Decrease
of 6.5 Percent; Adjusted Diluted EPS of $2.46, an Increase of 6.5
Percent; These Results Include an Unfavorable Impact of $0.13 Per Share
Related to Acquired IPR&D and Milestones Expense
-- Delivers First-Quarter Net Revenues of $13.343 Billion, an Increase of
8.4 Percent on a Reported Basis or 9.8 Percent on an Operational Basis
-- First-Quarter Global Net Revenues from the Immunology Portfolio Were
$6.264 Billion, an Increase of 16.6 Percent on a Reported Basis, or 18.1
Percent on an Operational Basis; Global Skyrizi Net Revenues Were $3.425
Billion; Global Rinvoq Net Revenues Were $1.718 Billion; Global Humira
Net Revenues Were $1.121 Billion
-- First-Quarter Global Net Revenues from the Neuroscience Portfolio Were
$2.282 Billion, an Increase of 16.1 Percent on a Reported Basis, or 17.0
Percent on an Operational Basis; Global Vraylar Net Revenues Were $765
Million; Global Botox Therapeutic Net Revenues Were $866 Million;
Combined Global Ubrelvy and Qulipta Net Revenues Were $433 Million
-- First-Quarter Global Net Revenues from the Oncology Portfolio Were
$1.633 Billion, an Increase of 5.8 Percent on a Reported Basis, or 7.5
Percent on an Operational Basis; Global Imbruvica Net Revenues Were $738
Million; Global Venclexta Net Revenues Were $665 Million; Global Elahere
Net Revenues Were $179 Million
-- First-Quarter Global Net Revenues from the Aesthetics Portfolio Were
$1.102 Billion, a Decrease of 11.7 Percent on a Reported Basis, or 10.2
Percent on an Operational Basis; Global Botox Cosmetic Net Revenues Were
$556 Million; Global Juvederm Net Revenues Were $231 Million
-- Raises 2025 Adjusted Diluted EPS Guidance Range from $11.99 - $12.19 to
$12.09 - $12.29, which Includes an Unfavorable Impact of $0.13 Per Share
Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date
Through the First Quarter 2025
NORTH CHICAGO, Ill., April 25, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2025.
"AbbVie's first-quarter results were well ahead of our expectations and reflect an excellent start to the year," said Robert A. Michael, chief executive officer, AbbVie. "The fundamentals of our business are strong and we continue to bolster our outlook with pipeline advancements and strategic investments. Based on the progress we are making, AbbVie is well positioned for the long term."
First-Quarter Results
-- Worldwide net revenues were $13.343 billion, an increase of 8.4 percent
on a reported basis, or 9.8 percent on an operational basis.
-- Global net revenues from the immunology portfolio were $6.264 billion,
an increase of 16.6 percent on a reported basis, or 18.1 percent on an
operational basis.
-- Global Skyrizi net revenues were $3.425 billion, an increase of 70.5
percent on a reported basis, or 72.0 percent on an operational
basis.
-- Global Rinvoq net revenues were $1.718 billion, an increase of 57.2
percent on a reported basis, or 59.7 percent on an operational
basis.
-- Global Humira net revenues were $1.121 billion, a decrease of 50.6
percent on a reported basis, or 49.5 percent on an operational
basis.
-- Global net revenues from the neuroscience portfolio were $2.282 billion,
an increase of 16.1 percent on a reported basis, or 17.0 percent on an
operational basis.
-- Global Vraylar net revenues were $765 million, an increase of 10.3
percent.
-- Global Botox Therapeutic net revenues were $866 million, an increase
of 15.8 percent on a reported basis, or 17.0 percent on an
operational basis.
-- Global Ubrelvy net revenues were $240 million, an increase of 17.8
percent on a reported basis, or 18.0 percent on an operational
basis.
-- Global Qulipta net revenues were $193 million, an increase of 47.6
percent on a reported basis, or 48.3 percent on an operational
basis.
-- Global net revenues from the oncology portfolio were $1.633 billion, an
increase of 5.8 percent on a reported basis, or 7.5 percent on an
operational basis.
-- Global Imbruvica net revenues were $738 million, a decrease of 11.9
percent.
-- Global Venclexta net revenues were $665 million, an increase of 8.3
percent on a reported basis, or 12.3 percent on an operational
basis.
-- Global Elahere net revenues were $179 million.
-- Global net revenues from the aesthetics portfolio were $1.102 billion, a
decrease of 11.7 percent on a reported basis, or 10.2 percent on an
operational basis.
-- Global Botox Cosmetic net revenues were $556 million, a decrease of
12.3 percent on a reported basis, or 10.7 percent on an operational
basis.
-- Global Juvederm net revenues were $231 million, a decrease of 22.2
percent on a reported basis, or 20.0 percent on an operational
basis.
-- On a GAAP basis, gross margin in the first quarter was 70.0 percent. The
adjusted gross margin was 84.1 percent.
-- On a GAAP basis, selling, general and administrative (SG&A) expense was
24.7 percent of net revenues. The adjusted SG&A expense was 24.6 percent
of net revenues.
-- On a GAAP basis, research and development (R&D) expense was 15.5 percent
of net revenues. The adjusted R&D expense was 15.4 percent of net
revenues.
-- Acquired IPR&D and milestones expense was 1.9 percent of net revenues.
-- On a GAAP basis, operating margin in the first quarter was 28.0 percent.
The adjusted operating margin was 42.3 percent.
-- Net interest expense was $627 million.
-- On a GAAP basis, the tax rate in the quarter was 22.4 percent. The
adjusted tax rate was 14.2 percent.
-- Diluted EPS in the first quarter was $0.72 on a GAAP basis. Adjusted
diluted EPS, excluding specified items, was $2.46. These results include
an unfavorable impact of $0.13 per share related to acquired IPR&D and
milestones expense.
Note: "Operational" comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates.
Recent Events
-- AbbVie announced that its board of directors unanimously elected chief
executive officer (CEO) Robert A. Michael to assume the additional
position of chairman of the board of directors, effective July 1, 2025.
He will succeed Richard A. Gonzalez, who formerly served as AbbVie's CEO
and has been chairman since the Company's formation in 2013.
-- AbbVie announced that the European Commission (EC) granted marketing
authorization to Rinvoq (upadacitinib) for the treatment of giant cell
arteritis (GCA) in adult patients. The approval was supported by data
from the pivotal Phase 3 SELECT-GCA trial which demonstrated that Rinvoq
achieved the primary endpoint of sustained remission and key secondary
endpoints, including reduction in disease flares, lower cumulative
steroid exposure and complete remission. This authorization marks the
eighth approved indication for Rinvoq in the European Union (EU).
-- At the Society of Gynecologic Oncology (SGO) Annual Meeting, AbbVie
announced final data analysis from the Phase 3 MIRASOL trial evaluating
the efficacy and safety of Elahere (mirvetuximab soravtansine-gynx) in
women with folate receptor alpha (FR )-positive platinum-resistant
ovarian cancer (PROC) compared to chemotherapy. At 30.5 months median
follow-up, treatment with Elahere continued to show significant
improvements in progression-free survival (PFS) and overall survival
(OS) compared to investigator's choice (IC) chemotherapy.
-- AbbVie and Xilio Therapeutics, a clinical-stage biotechnology company,
announced a collaboration and option-to-license agreement that will
combine AbbVie's oncology expertise with Xilio's proprietary
tumor-activation technology to develop novel immunotherapies, including
masked T-cell engagers, for people living with cancer.
-- AbbVie announced that it submitted a Biologics License Application (BLA)
to the U.S. Food and Drug Administration (FDA) for approval of
trenibotulinumtoxinE (BoNT/E) for the treatment of moderate to severe
glabellar lines. TrenibotulinumtoxinE is a first-in-class botulinum
neurotoxin serotype E characterized by a rapid onset of action as early
as 8 hours after administration and short duration of effect of 2-3
weeks. If approved, trenibotulinumtoxinE will be the first neurotoxin of
its kind available to patients.
-- Allergan Aesthetics announced that the Allergan Medical Institute (AMI)
will open three new state-of-the-art training centers in the U.S.,
expanding access to high-quality, tailored training for licensed
aesthetics providers. The first training center is scheduled to open in
Irvine, CA, with additional locations to follow in Atlanta, GA and
Austin, TX.
-- AbbVie and Gubra announced a license agreement to develop GUB014295
(ABBV-295), a potential best-in-class, long-acting amylin analog for the
treatment of obesity. This partnership marks AbbVie's entrance into the
obesity field and under the terms of the agreement, AbbVie will lead
development and commercialization of GUB014295 globally. Prior to the
close of the agreement, Gubra announced positive interim results from
Part A of a Phase 1 multiple ascending dose (MAD) study, which showed
that GUB014295 was well tolerated with body weight loss that was
sustained in a manner consistent with data from a previously announced
single ascending dose (SAD) study.
-- AbbVie announced that the FDA approved Emblaveo (aztreonam and
avibactam), as the first monobactam/ -lactamase inhibitor combination
antibiotic therapy to treat complicated intra-abdominal infections,
including those caused by Gram-negative bacteria. The approval of
Emblaveo was supported by prior findings regarding the efficacy and
safety of aztreonam for the treatment of complicated intra-abdominal
infections as well as clinical trial results from the Phase 3 REVISIT
study, which evaluated the efficacy, safety, and tolerability of
Emblaveo for the treatment of serious infections due to Gram-negative
bacteria.
Full-Year 2025 Outlook
AbbVie is raising its adjusted diluted EPS guidance for the full year 2025 from $11.99 - $12.19 to $12.09 - $12.29, which includes an unfavorable impact of $0.13 per share related to acquired IPR&D and milestones expense incurred year-to-date through the first quarter 2025. The company's 2025 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the first quarter of 2025, as both cannot be reliably forecasted. This guidance does not reflect the acquired IPR&D and milestones impact related to AbbVie and Gubra's licensing agreement to develop GUB014295, as that transaction closed after the first quarter of 2025. Additionally, this guidance is based on the existing trade environment and does not reflect any trade policy shifts, including pharmaceutical sector tariffs, that could impact AbbVie's business.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, neuroscience, oncology, and eye care - and products and services across our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X (formerly Twitter), Facebook, Instagram, YouTube or LinkedIn.
Conference Call
AbbVie will host an investor conference call today at 8:00 a.m. Central Time to discuss our first-quarter performance. The call will be webcast through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the call will be available after 11:00 a.m. Central Time.
Non-GAAP Financial Results
Financial results for 2025 and 2024 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accordance with GAAP and include all revenue and expenses recognized during the period. Non-GAAP results adjust for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses, and other specified items presented in the reconciliation tables later in this release. AbbVie's management believes non-GAAP financial measures provide useful information to investors regarding AbbVie's results of operations and assist management, analysts, and investors in evaluating the performance of the business. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Media: Investors:
Gabby Tarbert Liz Shea
(224) 244-0111 (847)
935-2211
Todd Bosse
(847)
936-1182
Jeffrey Byrne
(847)
938-2923
AbbVie Inc.
Key Product Revenues
Quarter Ended March 31, 2025
(Unaudited)
% Change vs. 1Q24
Net Revenues (in millions) Reported Operationala
U.S. Int'l. Total U.S. Int'l. Total Int'l. Total
---
NET REVENUES $9,979 $3,364 $13,343 10.4 % 2.9 % 8.4 % 8.3 % 9.8 %
Immunology 4,883 1,381 6,264 17.6 13.4 16.6 20.1 18.1
Skyrizi 2,919 506 3,425 76.2 43.9 70.5 52.3 72.0
Rinvoq 1,220 498 1,718 68.3 35.3 57.2 42.8 59.7
Humira 744 377 1,121 (58.0) (24.4) (50.6) (19.5) (49.5)
Neuroscience 1,972 310 2,282 15.0 24.0 16.1 31.0 17.0
Vraylar 763 2 765 10.3 13.1 10.3 20.2 10.3
Botox Therapeutic 723 143 866 18.2 4.8 15.8 11.4 17.0
Ubrelvy 233 7 240 17.6 23.3 17.8 29.3 18.0
Qulipta 172 21 193 34.2 >100.0 47.6 >100.0 48.3
Vyalev 6 57 63 n/m >100.0 >100.0 >100.0 >100.0
Duodopa 20 76 96 (19.4) (16.0) (16.7) (11.7) (13.3)
Other Neuroscience 55 4 59 (9.5) (1.0) (8.9) 6.5 (8.4)
Oncology 1,027 606 1,633 6.0 5.4 5.8 10.0 7.5
Imbruvicab 529 209 738 (13.3) (8.2) (11.9) (8.2) (11.9)
Venclexta 312 353 665 11.0 6.0 8.3 13.4 12.3
Elahere 165 14 179 >100.0 n/m >100.0 n/m >100.0
Epkinlyc 21 30 51 66.7 >100.0 89.8 >100.0 94.8
Aesthetics 640 462 1,102 (17.4) (2.4) (11.7) 1.6 (10.2)
Botox Cosmetic 295 261 556 (24.3) 6.9 (12.3) 11.1 (10.7)
Juvederm Collection 75 156 231 (29.0) (18.5) (22.2) (15.0) (20.0)
Other Aesthetics 270 45 315 (3.5) 18.1 (0.9) 23.2 (0.3)
Eye Care 221 285 506 (2.6) (8.0) (5.7) (2.0) (2.2)
Ozurdex 30 93 123 (12.1) (3.8) (6.0) 1.1 (2.4)
Lumigan/Ganfort 48 58 106 69.2 (6.8) 17.0 (0.5) 21.4
Alphagan/Combigan 26 34 60 68.5 (21.4) 1.9 (15.4) 6.3
Other Eye Care 117 100 217 (21.4) (7.1) (15.4) (0.2) (12.5)
Other Key Products 636 173 809 (7.2) (19.4) (10.1) (14.8) (9.0)
Mavyret 142 164 306 (0.7) (20.4) (12.3) (15.8) (9.6)
Creon 355 355 24.6 n/m 24.6 n/m 24.6
Linzess/Constella 139 9 148 (46.1) 3.1 (44.4) 9.3 (44.2)
a "Operational" comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the
prior year's foreign exchange rates.
b
Reflects profit sharing for Imbruvica international revenues.
c Epkinly U.S. revenues reflect profit sharing. International revenues reflect product revenues as well as profit sharing from
certain international territories.
n/m = not meaningful
AbbVie Inc.
Consolidated Statements of Earnings
(Unaudited)
(in millions, except per share data) First Quarter
Ended March 31
2025 2024
Net revenues $13,343 $12,310
Cost of products sold 4,002 4,094
Selling, general and administrative 3,293 3,315
Research and development 2,067 1,939
Acquired IPR&D and milestones 248 164
Total operating costs and expenses 9,610 9,512
Operating earnings 3,733 2,798
Interest expense, net 627 453
Net foreign exchange loss 4 4
Other expense, net 1,441 586
Earnings before income tax expense 1,661 1,755
Income tax expense 372 383
Net earnings 1,289 1,372
Net earnings attributable to noncontrolling interest 3 3
Net earnings attributable to AbbVie Inc. $1,286 $1,369
Diluted earnings per share attributable to AbbVie Inc. $0.72 $0.77
Adjusted diluted earnings per sharea $2.46 $2.31
Weighted-average diluted shares outstanding 1,772 1,773
a Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information
for further details.
AbbVie Inc.
Reconciliation of GAAP Reported to Non-GAAP Adjusted Information
(Unaudited)
1. Specified items impacted results as follows:
Quarter Ended March 31, 2025
(in millions, except per share data)
Earnings Diluted
Pre-tax After-taxa EPS
As reported (GAAP) $1,661 $1,286 $0.72
Adjusted for specified items:
Intangible asset amortization 1,858 1,574 0.89
Change in fair value of contingent consideration 1,518 1,477 0.83
Other 62 33 0.02
As adjusted (non-GAAP) $5,099 $4,370 $2.46
a Represents net earnings attributable to AbbVie Inc. Specified items reflect the impact of applicable statutory tax rates.
Reported GAAP earnings and adjusted non-GAAP earnings for the three months ended March 31, 2025 included acquired
IPR&D and milestones expense of $248 million on a pre-tax and $238 million on an after-tax basis, representing an
unfavorable impact of $0.13 to both diluted EPS and adjusted diluted EPS.
2. The impact of the specified items by line item was as follows:
Quarter Ended March 31, 2025
(in millions) Cost of SG&A R&D Other
products expense,
sold net
As reported (GAAP) $4,002 $3,293 $2,067 $1,441
Adjusted for specified items:
Intangible asset amortization (1,858)
Change in fair value of contingent consideration - (1,518)
Other (28) (13) (16) (5)
As adjusted (non-GAAP) $2,116 $3,280 $2,051 $(82)
3. The adjusted tax rate for the first quarter of 2025 was 14.2 percent, as detailed below:
Quarter Ended March 31, 2025
(dollars in millions) Pre-tax Income taxes Tax
rate
earnings
As reported (GAAP) $1,661 $372 22.4 %
Specified items 3,438 354 10.3 %
As adjusted (non-GAAP) $5,099 $726 14.2 %
AbbVie Inc.
Reconciliation of GAAP Reported to Non-GAAP Adjusted Information
(Unaudited)
1. Specified items impacted results as follows:
Quarter Ended March 31, 2024
(in millions, except per share data)
Earnings Diluted
Pre-tax After-taxa EPS
As reported (GAAP) $1,755 $1,369 $0.77
Adjusted for specified items:
Intangible asset amortization 1,891 1,603 0.90
Acquisition and integration costs 511 486 0.27
Change in fair value of contingent consideration 660 643 0.36
Other 21 19 0.01
As adjusted (non-GAAP) $4,838 $4,120 $2.31
a Represents net earnings attributable to AbbVie Inc. Specified items reflect the impact of applicable statutory tax rates.
Acquisition and integration costs primarily reflect costs related to the ImmunoGen acquisition.
Reported GAAP earnings and adjusted non-GAAP earnings for the three months ended March 31, 2024 included acquired
IPR&D and milestones expense of $164 million on a pre-tax and $138 million on an after-tax basis, representing an
unfavorable impact of $0.08 to both diluted EPS and adjusted diluted EPS.
2. The impact of the specified items by line item was as follows:
Quarter Ended March 31, 2024
(in millions) Cost of SG&A R&D Interest Other
products expense, expense,
sold net net
As reported (GAAP) $4,094 $3,315 $1,939 $453 $586
Adjusted for specified items:
Intangible asset amortization (1,891)
Acquisition and integration costs (79) (280) (128) (24)
Change in fair value of contingent consideration - (660)
Other (16) (3) (2)
As adjusted (non-GAAP) $2,108 $3,032 $1,811 $429 $(76)
3. The adjusted tax rate for the first quarter of 2024 was 14.8 percent, as detailed below:
Quarter Ended March 31, 2024
(dollars in millions) Pre-tax Income taxes Tax
rate
earnings
As reported (GAAP) $1,755 $383 21.8 %
Specified items 3,083 332 10.8 %
As adjusted (non-GAAP) $4,838 $715 14.8 %
View original content to download multimedia:https://www.prnewswire.com/news-releases/abbvie-reports-first-quarter-2025-financial-results-302437978.html
SOURCE AbbVie
